学会等発表 - 山本　竜平

Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon’s experience

Numakura K.

World Journal of Surgical Oncology  2022年12月  -  2022年12月    World Journal of Surgical Oncology

DOI

Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients

Yagishita H.

International Journal of Molecular Sciences  2022年10月  -  2022年10月    International Journal of Molecular Sciences

DOI

Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel

Narita S.

International Journal of Clinical Oncology  2022年09月  -  2022年09月    International Journal of Clinical Oncology

DOI

A CASE OF RENAL ANASTOMOSING HEMANGIOMA

Sasaki Y.

Acta Urologica Japonica  2022年08月  -  2022年08月    Acta Urologica Japonica

A 65-year-old man was found to have a 1.7 cm right renal mass by follow-up abdominal computed tomography for left total nephrectomy after a traffic accident. The renal mass progressed slowly to 2.2 cm in three years and enhanced magnetic resonance imaging revealed marked T2 weighting hyperintensity of the lesion. Although a radiologist (TK) suggested the diagnosis renal anastomosing hemangioma preoperatively, we could not deny the possibility of renal cell carcinoma completely. Therefore, the patient underwent robot-assisted laparoscopic partial nephrectomy. The tumor was successfully removed without any renal arterial clamping or parenchymal excision. Histopathologically, the lesion was composed of capillary-size blood vessels lined by a single layer of endothelial cells, and was diagnosed as a renal anastomosing hemangioma. There were no signs of postoperative recurrence during the 3 month follow-up.

DOI

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism

Kobayashi M.

Genes  2022年07月  -  2022年07月    Genes

DOI

Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate

Takahashi Y.

European Journal of Clinical Pharmacology  2022年  -  2022年    European Journal of Clinical Pharmacology

DOI

Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy

Narita S.

World Journal of Urology  2022年  -  2022年    World Journal of Urology

DOI

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab

Takahashi S.

Cancer Science  2022年  -  2022年    Cancer Science

DOI

Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study

Numakura K.

European Urology Focus  2022年  -  2022年    European Urology Focus

DOI

術前肥満が腎移植後のアウトカムに与える影響についての検討

山本　竜平，他

第25回秋田腎不全研究会  2021年11月  -  2021年11月   

Preoperative rebound of anti-ABO blood type antibody is a risk f actor of acute antibody-mediated rejection in kidney transplant recipients even in rituximab era

Ryohei Yamamoto, et al

American Urological Association2021  2021年09月  -  2021年09月   

マウス腎虚血／再灌流障害モデルにおける制御性T細胞の腎保護効果の検討

山本　竜平，他

第86回日本泌尿器科学会東部総会  (旭川)  2021年09月  -  2021年09月   

術前肥満が腎移植後のアウトカムに与える影響についての検討

山本　竜平，他

第57回　日本移植学会総会  2021年09月  -  2021年09月    東京

秋田大学における腎移植後の移植後リンパ増殖性疾患の検討

山本　竜平，他

第36回腎移植・血管外科研究会  (長崎)  2021年06月  -  2021年06月   

秋田大学での免疫学的リスク別免疫抑制プロトコールの評価

山本　竜平，他

第５４回日本臨床腎移植学会  (福島)  2021年02月  -  2021年02月    日本臨床腎移植学会